login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
AVENUE THERAPEUTICS INC (ATXI) Stock News
USA
- NASDAQ:ATXI -
US05360L4032
-
Common Stock
0.42
USD
-0.43 (-50.71%)
Last: 3/18/2025, 8:23:22 PM
0.3998
USD
-0.02 (-4.81%)
After Hours:
3/18/2025, 8:23:22 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ATXI Latest News, Press Relases and Analysis
All
Press Releases
6 months ago - By: Benzinga
- Mentions:
RGC
TNXP
SRPT
JAGX
...
12 Health Care Stocks Moving In Tuesday's Intraday Session
a year ago - By: BusinessInsider
ATXI Stock Earnings: Avenue Therapeutics Misses EPS for Q2 2024
a year ago - By: InvestorPlace
ATXI Stock Earnings: Avenue Therapeutics Misses EPS for Q2 2024
a year ago - By: BusinessInsider
ATXI Stock Earnings: Avenue Therapeutics Misses EPS for Q1 2024
6 months ago - By: Benzinga
- Mentions:
HMR
ANTE
SYRS
AGMH
...
Dow Dips Over 200 Points; US Industrial Production Increases More than Expected
a year ago - By: InvestorPlace
ATXI Stock Earnings: Avenue Therapeutics Misses EPS for Q1 2024
10 months ago - By: Avenue Therapeutics
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
a year ago - By: Avenue Therapeutics
Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit
1 years ago - By: InvestorPlace
ATXI Stock Earnings: Avenue Therapeutics Beats EPS for Q4 2023
1 years ago - By: BusinessInsider
ATXI Stock Earnings: Avenue Therapeutics Beats EPS for Q4 2023
a year ago - By: Avenue Therapeutics
Avenue Therapeutics to Participate in Upcoming Investor Conferences
a year ago - By: Avenue Therapeutics
Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
a year ago - By: Avenue Therapeutics
Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
a year ago - By: Avenue Therapeutics
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
a year ago - By: Avenue Therapeutics
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
a year ago - By: Avenue Therapeutics
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
a year ago - By: Avenue Therapeutics
Avenue Therapeutics Announces Reverse Stock Split
1 years ago - By: Avenue Therapeutics
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
Please enable JavaScript to continue using this application.